Mrtx1719 matching placebo

A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion

A randomized, phase 2/3 study comparing BMS-986504 in combination with Nab-paclitaxel and Gemcitabine versus placebo in combination with Nab-paclitaxel and Gemcitabine in participants with untreated metastatic pancreatic ductal adenocarcinoma harboring homozygous MTAP deletion